Equity ETF ChannelBiotech ETFs Make Gains Tuesday, Despite the J&J Vaccine PauseBy Ian YoungApril 13, 2021
Equity ETF ChannelJohnson & Johnson, UnitedHealth Give Healthcare ETFs a Much Needed Bolster ShotBy Max ChenOctober 15, 2019
Innovative ETFs ChannelPotential Peanut Allergy Treatment Gives Pharma Company A BoostBy Ian YoungSeptember 11, 2019
Beyond Basic Beta Channel8 ETFs to Capture Opportunities in Healthcare SectorBy Max ChenAugust 22, 2019
Thematic Investing ChannelJohnson & Johnson Could Be A Good Bet Despite Opioid LawsuitBy Ian YoungJuly 8, 2019
Innovative ETFs ChannelAbbVie, Allergan Deal Puts Spotlight on Pharmaceutical ETFsBy Max ChenJune 25, 2019
Beyond Basic Beta Channel4 ETFs to Consider with Big Pharma on the Senate’s Hot SeatBy Ben HernandezApril 9, 2019
Equity ETFsHealthcare ETFs Looked Pale on Reports J&J Knew About Asbestos in Baby PowderBy Max ChenDecember 14, 2018
Equity ETFsGetting Defensive With Healthcare ETFs as Congress Moves to Replace ObamacareBy Tom LydonMay 8, 2017
